Augusto Silva

MEDICAL DEVICES HELPING PLATFORMS
From experimental data to clinical decisions
ALTHIA
Augusto Silva
Director de I+D
Focus Areas
Clinical information
Clinical data, Images
Basic experimental
Research
Basic experimental
Research
Advance
Diagnostics
Single doses
radiotherapy
R&D
New technologies
cancer markers, stem cell research, e.diagnostics, Nanotechnology,
inflammatory tissue, high-doses radiobiology
Antitumoral Therapy
Single dose Sterotactic body Radiotherapy
• HIGH DOSES(24 Gy)
• More EFFECTIVE
• More PRECISED
• LOW COLATERAL DAMAGE
• AMBULATORY TREATMENT
• COMPLEX BODY AREAS
• MICROMESTASTASIS
DEVELOPMENT OF MANAGEMENT FOR HIGH RESOLUTION IMAGES
GENERATION OF PREDICTIVE ALGORITHMS
SCAN IMAGES
COMPILATION
BODY
STEREOTACTIC
RADIOTHERAPY
CLINICAL IMAGE
MANAGEMENT
SINGLE CELL RESPONSE
MOA
GPS STEREOTACTIC
RADIOTHERAPY
TISSUE MULTIPLEX
IN VIVO
CELL
MOVEMENT
4
TradionP
System Expert prototype of personalized of
diagnostic and treatment for oncology
patients
Haga clic para modificar el estilo de subtítulo del
patrón
13/09/2012
New focus
Personalized Medicine requires a profound knowledge on
the biology of the diseases and the continuous
incorporation of new technologies.
• Tools for the
appropriate
integration and
incorporation of all
clinical data
Bioinformatic
solutions
• Automated
processing of data for
diagnostic and
treatment
• Artifical Intelligent
Algorithms
• Multidisciplinar and
multicentric approach
of the oncological
diseases
• Especialist
networking
Convenience
Objetivity
Universality
6
Multimodal Database
Tradion P Multimodal database stores all patient
information
Patients Data
Genotyping
Clinical Data
Histopatology
Image
Epigenetics
FunctionalHi
stology
FISH
7
INTEGRAL CONCEPT
PREDICTION
RISK VALUE
EARLY
DETECTION
STRATIFICATION
& THERAPEUTIC PLAN
FOLLOW UP &
DRUG RESPONSE
SNPs
GENOMICS
RT-PCR
Proteomics
MALDI-TOF
Molecular Pathology
Morfometry/Multiplexing
Proteomics
Genomics
Molecular Citology
RT-PCR
NON INVASIVE DIAGNOSTICS
BODY fluids /
Exfoliative cells
Tissue biopsies/ samples
AUTOMATED
DEVICES
TECHNOLOGICAL ADVANCES
IN MOLECULAR BIOLOGY
CGH-DNA
cDNA-RNA
Simplicity
Complexity
Single Markers
Multiple markers
Clinical relevance
Discovery tools
PROTEÓMICA
vs.
Daily applications
 Genetic products from different sources
 Losing micro-anatomical complexity
 Losing tissue heterogeneity
TECHNOLOGICAL ADVANCES
IN SYSTEM PATHOLOGY
Fingerprint
Genomic
&
Proteomic
Multiespectral
Image
DATA MINING
&
Automated learning
(Artificial Intelligence)
10
ADVANCES IN INTEGRATION
OF THE INFORMATION
CTC
CONTROL
CA PRÓSTATA
Proteomic
Biopsies
Image guide
INTEGRATION OF
DIAGNOSTIC ARSENAL
Plasma screening
Molecular Pathway
Identified and cell removal
Radiology
ECGs
Proteomics
Dermatology
Nanotechnology
Pathology
Experimental
data
Oftalmology
Endoscopy
Cell culture
Ecografy
Genomics
Robotics
Screening
Imagen
Capture
& standarization of
Medical Image
Especialists
DICOM
Web platform for
Image and data exchange
Local
Information
Unit
Medical Personalized Platform,
Interoperable and with Clinical
Decisions Support
Engine Rules
Description of the Clinical Decision System
1. The clinical specialist demand a
query to the System.
2. The System offers a possible
treatment based on the internal
knowledge.
Beneficts of the System to Clinical Decisions
 Decision helper
 Personalized Treatment
 Cost savings
 Reliable
 Faster response
 Resources increase
 Time saver
 Increase availability
 Homogenized criteria
New alternatives
• Identification of cancer risk in fluids
– Cancer markers (exosoms: miRNA, lncRNA, proteins,
metabolites, free DNA carrying cancer mutations)
• Colorectal carcinomas in plasma (en preparation)
• Lung cancer in plasma, urine & sputum (en preparation)
• Brain tumors in plasma and LCR (en preparation)
• Biomarker robotic detection (nanotech:
graphene/biosensors)
•
•
• Localization of brain damage following the tissue repair
process through integral MRI clinical images.
Running &
In development
DISEASES
COMMENTS
HOSPITALS
Breast and Colorectal
Cancer predictor
H V d Nieves & HUSC
Prostate Cancer
Cancer Predictor
H Clinic/H VdH/ H 12O/
Hepatic Carcinoma
Kinase inhibitors
H Marañon Dr. JA Lopez
Gastric Carcinoma
MAPKs pathway
H Sant Pau; Dr. Barnada
Breast Cancer
Breast, sentinel and CTC H. V Nieves Dr. JL Puche
Astrocytoma Grade III
Stratification markers
IDIBELL, Dr. I. Ferrer
Colorectal Cancer
Automate device marker
CAPIO. Dr. JG. Foncillas
Lung Cancer. NSCLC
Metabolites sputum
H. Malaga. Dr E. Alba
Autoimmune LUPUS
Damage Tissue Mplex
Genyo Dra. M. Alarcon-R
Non-Hodking lymphomas EGFR & PTEN
Clinic. Dr. E. Campo
Brain damage. Alzheimer Pre-lesion areas
IDIBELL. Dr. I Ferrer
16
ALTHIA CONTACTS
• Augusto Silva
– Director R&D
– asilva@althia.es
– Phone: 629787403
多谢
17
BACKUP SLIDES
• Responsable Registro
del Cáncer (EASP)
Registro
• Inserta Información
clínica del paciente
• Responsables
Oncólogos (HUSC y
HUVN)
Clínicos
• Inserta Información
Radiológica (TAC,
Mamografía, RX, etc.)
• Responsable
Radiólogos (HUSC y
HUVN)
Radiología
• Inserta Información
Histopatológica y
verifica si la muestra
tumoral es apta
• Responsables
Patólogos (HUSC
HUVN)
Histopatología
• Lee la información
insertada por el resto
de las OPI’s y la
contrasta
• Responsable Biobanco
Andaluz
Control de
Calidad
TradionP
• Inserta información de
los pacientes
seleccionados para el
estudio
19
PROTOTIPO DE SISTEMA EXPERTO DE TRATAMIENTO Y DIAGNÓSTICO ONCOLÓGICO
PERSONALIZADO PARA ENFERMOS DE CÁNCER..
02 TradionP
Mapa de Módulos de los Organismos Públicos (Datos Clínicos)
• Inserta en la Base de
Datos Multimodal los
Datos Epigeneticos de
las muestras
analizadas
• Inserta en la Base de
Datos los datos
Multimodal los datos de
Histología Funcional de
las muestras analizadas
• Responsable Lorgen
• Responsable Lorgen
• Responsable Althia
Genotipado
Datos
Eipigenéticos
Histología
Funcional
• Inserta en la Base de
Datos los datos
Multimodal los datos
FISH de las muestras
analizadas
• Los responsables
científicos analizan la
Información Insertada
en la Base de Datos
Multimodal
• Responsable Althia
• Responsable Althia
Hibridación in Situ
Fluorescente
(FISH)
Análisis de la
Información
20
PROTOTIPO DE SISTEMA EXPERTO DE TRATAMIENTO Y DIAGNÓSTICO ONCOLÓGICO
PERSONALIZADO PARA ENFERMOS DE CÁNCER..
• Inserta en la Base de
Datos Multimodal los
datos de Genotipado
de las muestras
analizadas
TradionP
02 TradionP
Mapa de Módulos del los Organismos Privados (Datos Experimentales)
• Acceso a los datos del
Sistema para probar y
Desarrollar los Algoritmos
de Data Mining
• Responsable Centro de
Investigaciones Príncipe
Felipe (CIPF)
TradionP
Algoritmos de
Data Mining
21
PROTOTIPO DE SISTEMA EXPERTO DE TRATAMIENTO Y DIAGNÓSTICO ONCOLÓGICO
PERSONALIZADO PARA ENFERMOS DE CÁNCER..
02 TradionP
Módulos del Centro de Investigaciones Príncipe Felipe
•
•
•
•
Coordinación del Proyecto
Diseño del Sistema
Desarrollo del Sistema Experto
Administración de los Sistemas
• Responsable Indra.
22
PROTOTIPO DE SISTEMA EXPERTO DE TRATAMIENTO Y DIAGNÓSTICO ONCOLÓGICO
PERSONALIZADO PARA ENFERMOS DE CÁNCER..
TradionP
Desarrollo del Prototipo y
Coordinación del Proyecto
02 TradionP
Acceso de Indra
Summary:
Areas for synergy / collaboration
•
Assessment of novel / known (bio)markers with IHC, and / or quantitative multiplex IF
(i.e. develop future companion diagnostics).
•
Incorporate molecular diagnostic strategies including FISH, RT-PCR, sequencing, and
CTC’s to define clinical phenotypes – provide precision diagnostics.
•
Construct clinical – systems ‘machine learning’ models.
•
Support pre-clinical animal and in vitro model development through existing systemspathology platform.
•
Access to various disease-focused clinical bio-specimens (tissues / fluids) for
investigation, discovery and confirmation studies.
•
Access to a regulatory-centric, multi-purpose, clinical translational laboratory.
•
Network with clinical-academic and EU / US biotechnology centers for consultation –
collaboration.
A comprehensive approach
To Clinical R&D
CLINICAL ISSUES
R&D PROGRAMS
CLINICAL TRIALS
Optimization
of Trials
Molecular
Classification
PRECLINICAL STUDIES
EXPERIMENTAL THERAPEUTICS
EXPERIMENTAL PATHOLOGY
Biological
end-points
Resistance
Mechanisms
Markers of Tumor
Progression
Decision Making
Tools Impacting
on Management
DISCOVERY STUDIES
MOLECULAR PROFILING
COMPUTATIONAL BIOLOGY
Pathway Analysis
VALIDATION ANALYSES
MOLECULAR PATHOLOGY
CANCER BIOLOGY STUDIES
IN VIVO
Tumor Xenografts
Transgenic Models
Human Samples
IN VITRO
Cell Lines
Expression and
Functional Assays
Identification
Candidate Genes
Lab Facilities, Barcelona
Lab Facilities, Granada
26
Professional Team
• Board of Directors
Santiago de Torres Sanahuja, President
Isabel Lozano Fernández, Executive Vice President
Carlos Cordón-Cardo, Vice President of Scientific Affairs
Zvi Fuchs, Vice President of Medical Affairs
• Management Team
Michael Donovan, Chief Scientific Officer
Pedro Salord Bertrán, Chief Financial Officer
Lola Casals Marull, Director of Communications
Augusto Silva González, R&D Director
Anna Colomer Valero, Diagnostics Director
Alicia Domingo Claros, Director of Hematology
Antonio López-Beltrán, Director of Pathology
Nadina Erill Sagalés, Technical Director